Retatrutide 20mg/mL — 5mL

What is Retatrutide?

Retatrutide is a triple agonist peptide — meaning it activates three metabolic receptors simultaneously: GIP, GLP-1, and glucagon. It represents the newest generation of weight management peptides, currently advancing through Phase 3 clinical trials. Its multi-receptor design is intended to address weight, metabolic rate, and energy expenditure from three distinct angles at once.

How It Works

The glucagon receptor adds a third dimension to the dual-agonist approach of tirzepatide. Glucagon stimulates the liver to increase energy expenditure and supports fat breakdown (lipolysis). Combined with the appetite and insulin effects of GIP and GLP-1 activation, this triple-pathway approach targets caloric intake, fat metabolism, and energy output simultaneously — a mechanism unlike any previously approved therapy.

Key Benefits

Early Phase 2 trial data for retatrutide showed average weight reductions approaching 24% of body weight at higher doses over 48 weeks — preliminary figures that surpassed other agents in equivalent trial designs. Metabolic markers including triglycerides, blood sugar, and liver fat also improved in study participants. As Phase 3 data continues to emerge, retatrutide is positioned as a significant advance in peptide-based metabolic therapy.

What to Expect

Because retatrutide is newer, clinical protocols are still being refined. Current compounded use follows a gradual titration approach similar to other GLP-1 class peptides. Patients and prescribers should discuss timelines and dosing expectations carefully. As with other agents in this class, gastrointestinal adjustment is common at the beginning of therapy.

Quality & Sourcing

Every retatrutide formulation from Greenstone Peptides is compounded in the USA by licensed pharmacy partners under USP 797 sterile standards. Each batch is third-party tested for potency, sterility, and endotoxin.